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AbstrAct
Previous studies suggest that serum myeloperoxidase (MPO) is a potentially useful biomarker to risk strat-
ify troponin-negative patients with suspected myocardial ischemia. We hypothesized that the relationship 
between initial serum MPO levels would correlate with 30-day adverse cardiac outcomes for low risk emer-
gency department (ED) patients with suspected myocardial ischemia. this prospective cohort study enrolled 
ED patients with chest pain or suspected myocardial ischemia, non-diagnostic EcG, and initially negative 
cardiac troponin I. We defined 30-day adverse cardiac events as death, myocardial infarction, or coronary 
revascularization. We calculated summary statistics, standard deviation (SD), odds ratios (OR), 95% confi-
dence intervals (cI), and receiver operating characteristics (rOc). We enrolled 159 patients who had a mean 
age of 55 ± 13, were 56% female, of whom 5.2% suffered at least one adverse cardiac event. MPO test charac-
teristics were poor, with an rOc area of only 0.47 (cI 0.23-0.71). MPO levels were not associated with adverse 
events (Or 0.99, cI 0.98-1.01, p=0.62). the optimal rOc cutpoint to predict adverse cardiac events had poor 
sensitivity and specificity (57% and 52%, respectively). Mean MPO concentrations in the event group did not 
differ from the non-event group.  In this limited cohort of low risk ED patients with chest pain, we were unable 
to demonstrate utility of MPO for risk stratification. If confirmed in larger studies, these findings may call into 
question the routine use of MPO for low-risk chest pain. (Int J Biomed Sci 2009; 5(2):129-135)
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INtrODUctION
Inflammatory events are implicated in all phases of 
the evolution of the coronary atherosclerotic plaque (1). 
Myeloperoxidase (MPO), a member of the heme-peroxi-
dase superfamily, is a potential participant in the coro-
nary atherogenic process (2). MPO-catalyzed reactions 
are linked with development of endothelial dysfunction 
(3), generation of atherogenic lipoproteins (4), and con-
sumption of nitric oxide (5). Mechanistic links implicate 
MPO with the initiation and propagation of the mature 
atheroma (6), as well as complications of acute plaque 
rupture (7, 8). 
In human subjects, MPO levels are correlated with an-
giographic evidence of atherosclerotic plaque (9). Serum 
MPO levels have prognostic value at 30-days and 6 months 
for emergency department (ED) patients with chest pain 
(10), as well as patients with acute coronary syndromes 
enrolled in the CAPTURE study (11). 
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The potential clinical utility of MPO for use in indi-
vidual patients, while promising, remains unclear. Tests 
to assay serum MPO levels will soon become commer-
cially available, but the test characteristics and timing of 
possible MPO elevation in acute coronary syndromes are 
unknown. Furthermore, low risk populations remain an 
important but as yet unstudied population of interest for 
potential risk stratification with MPO. A biomarker with 
high sensitivity would allow for potential safe discharge 
home for a large proportion of patients. We conducted a 
prospective, observational study to evaluate whether se-
rum MPO levels predict 30-day adverse cardiac outcomes 
for low-risk ED patients with suspected myocardial isch-
emia. 
MEtHODs
selection and Description of Participants
This  was  a  prospective,  cohort  study  that  analyzed 
the association between serum MPO levels and 30-day 
adverse cardiac events for low risk ED patients with sus-
pected myocardial ischemia. The study and protocol for 
written informed consent were approved by the Institu-
tional Review Board at the study institution.
The study institution was an urban, tertiary-care hos-
pital with an annual census of approximately 55,000 adult 
visits. The ED was staffed by board-certified emergency 
physicians 24 hours per day. 
Our population included a convenience sample (dur-
ing business hours and only when research personnel were 
available) of low risk ED patients with chest pain or symp-
toms suggestive of myocardial ischemia. We defined low 
risk patients as those with non-diagnostic electrocardio-
gram (ECG) and negative initial cardiac markers (creatine 
kinase isoenzyme MB and cardiac troponin I). Patients 
with  suspected  unstable  angina  (based  on  the  impres-
sion of the attending emergency physician), unstable vital 
signs, or any ECG changes consistent with acute ischemia 
or infarction were excluded. 
Patients  meeting  inclusion  criteria  were  approached 
for enrollment by either a research assistant or a co-in-
vestigator. Written informed consent was obtained for all 
subjects. Study staff members completed a questionnaire 
identifying demographics and cardiac risk factors. 
Enrolled patients were admitted to the ED chest pain 
observation unit. All patients were pain-free on arrival to 
the unit and were placed on telemetry monitoring. Serial 
ECGs and cardiac markers (total creatine kinase, creatine 
kinase isoenzyme MB and troponin I) were performed 
over an 8 hour period. Patients with resolved symptoms 
and negative serial cardiac markers underwent either inpa-
tient or outpatient stress testing at the discretion of the ED 
attending physician. Follow-up chart review of electronic 
medical records and a telephone call after 30 days were 
performed by one of the co-investigators. 
Cardiac markers were measured using Bayer reagents 
(Bayer Healthcare, Cambridge, MA) on the Bayer Advia 
Centaur  analyzer.  Standard  cutoff  concentrations  were 
used for total creatine kinase (41-266 units/liter), creatine 
kinase MB (0-5 ng/ml), and cardiac troponin I (0-0.10 ng/
ml). 
technical Information
Serum was drawn from patients upon completion of 
informed consent to the study. Serum acquisition occurred 
within 8 hours of arrival to the ED. No repeat samples 
were acquired. Blood was drawn into heparin-free tubes 
and centrifuged for ten minutes at 800 rpm. Plasma was 
separated from cells by pipetting into 500 micro-liter ali-
quots and stored at minus-20 degrees Celsius. 
Plasma  was  shipped  on  dry  ice  to  an  independent, 
blinded  laboratory  (Oxford  Biomedical  Research,  Ox-
ford, MI) for measurement of MPO levels (in picomoles 
per liter, or pM) using the Oxis MPO-EIA kit (Oxis In-
ternational, Inc., Foster City, CA). The MPO assay is a 
sandwich immunoassay to which plasma was added and 
used to measure the MPO concentration by detection of 
a fluorescence signal. Assay sensitivity was determined 
from eight individual measurements performed on stan-
dard curves from 4 separate runs, on the same day. The 
sensitivity signal was determined as 3.3 times the mean 
standard deviation of the 0 ng/ml standard from the in-
dividual curves. A linear extrapolation was made of this 
signal with the mean of 4 signal curves, and an interas-
say sensitivity was determined. Observed cross reactivity 
with eosinophil peroxidase is < 2%. 
The composite outcome was 30-day adverse cardiac 
events, defined as any of the following: death, myocardial 
infarction (per the Joint European Society of Cardiology/ 
American College of Cardiology criteria) (12), and coro-
nary revascularization (defined as percutaneous coronary 
intervention or coronary artery bypass grafting).  
statistics
To calculate anticipated sample size, we assumed a 
5% incidence of adverse cardiac events (based on data 
from prior chest pain unit cohorts) (13-15), mean MPO 
levels  of  80  (estimated  standard  deviation:  40)  in  the myeloperoxIdase for chest paIn
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adverse event group and 50 (estimated standard devia-
tion: 25) in the event free group (estimated from previ-
ous cohorts) (10-11). Using these assumptions with the 
“sampsi” command of STATA, we calculated the need to 
enroll 123 patients in the event-free group and 7 patients 
in the adverse event group to have 80% power (with 0.05 
alpha) to detect a significant difference in mean MPO 
levels with the Student’s t-test. 
For  the  primary  analysis,  Intercooled  STATA  (ver-
sion 8.2) was utilized to calculate Fisher’s exact test (two-
tailed) and Student’s t-test for categorical and continuous 
variables, respectively. Odds ratios (OR) based on univari-
ate analysis, 95% confidence intervals (CI), and receiver 
operating characteristics (ROC) were also assessed (16). 
For our secondary data analysis, we defined the optimal 
MPO cutpoint as that which minimizes the difference be-
tween the false negative frequency and the false positive 
frequency (17). Using this cutpoint, we calculated the sen-
sitivity and specificity of MPO for 30-day adverse cardiac 
events. All p values were two-tailed with one degree of 
freedom, with a value <0.05 considered significant. 
rEsULts
clinical characteristics
Of 159 patients meeting inclusion criteria, 24 patients 
(15%) were lost to follow-up, yielding 135 patients (85%) 
for data analysis. The clinical characteristics for all pa-
tients evaluated in the study are shown in Table 1. Patients 
lost to follow-up tended to be younger, but otherwise had 
similar clinical characteristics to those with follow-up data 
(Table 2). 
Cardiac  markers  associated  with  adverse  events  in-
cluded mean initial creatine kinase isoenzyme MB levels 
(p=0.049), mean serial creatine kinase levels (p<0.0001), 
and  mean  serial  creatine  kinase  isoenzyme  MB  levels 
(p<0.0001). There was not a statistically significant differ-
ence between mean MPO levels for patients with (61.7 pM, 
table 1. Baseline clinical characteristics
Characteristic
All Patients Patients with adverse events Patients without adverse events
p Value
No. (%) (n=135) No. (%) (n=7) No. (%) (n=128)
Mean Age (+/- SD) 54.9 +/- 12.8 52.9 +/- 9.9 55 +/- 12.98 NA
Male Gender 60 (44) 4 (57) 56 (44) NA
Cocaine Use Within 24 Hours 2 (1) 0 (0) 2 (2) NA
Prior MI 7 (5) 1 (14) 6 (5) NA
Cardiac Risk Factors
  Current Smoker 23 (17) 2 (29) 21 (16) NA
  Hypertension 62 (46) 4 (57) 58 (45) NA
  Hypercholesterolemia 53 (39) 2 (29) 51 (40) NA
  Family History 45 (33) 4 (57) 41 (32) NA
  Diabetes Mellitus 21 (16) 2 (29) 19 (15) NA
Cardiac Markers
  Mean Initial Total CK (U/L) 119.5 148.6 117.9 0.31†
  Mean Serialb Total CK (U/L) 121.6 464.0 102.1 <0.0001a
  Mean Initial MB (ng/ml) 1.6 2.5 1.5 <0.05a
  Mean Serialb MB (ng/ml) 3.3 39.6 1.25 <0.0001a
  Mean Initial Troponin I (ng/ml) <0.01 <0.01 <0.01 1.0a
  Mean MPO (pM) 78.3 61.7 79.2 0.62a
Mean ACI-TIPI Score 17.6 19.7 17.5 0.73a
TOTAL 135 (100) 7 (5.2)  128 (94.8)
Significant p values are in bold; aStudent t-test for continuous variables; bSerial serum measurements indicate results of the second set drawn 
after 8 hours. SD, standard deviation; MI, myocardial infarction; CK, creatine kinase; MB, creatine kinase isoenzyme MB; MPO, myelo-
peroxidase; ACI-TIPI, acute cardiac ischemia time insensitive predictive instrument; ng, nanograms; mg, milligrams; U, units; L, liter; ml, 
milliliter; pM, picomolar; NA, not applicable.myeloperoxIdase for chest paIn
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table 2. Characteristics of patients lost to follow-up
Characteristic
All Patients Patients LTFU Patients With Follow-up
p Value
No. (% orSD) No. (% or SD) No. (% or SD)
Mean Age (+/- SD) 53.9 (12.5) 48.0 (8.3) 54.9 (12.8) 0.011c
Male Gender 75 (47) 15 (63) 60 (44) 0.12a
Cocaine Use Within 24 Hours 3 (2) 1 (4) 2 (2) 0.39a
Prior MI 7 (4) 0 (0) 7 (5) 0.60a
Cardiac Risk Factors
  Current Smoker 26 (16) 3 (13) 23 (17) 0.77a
  Hypertension 74 (47) 12 (50) 62 (46) 0.71b
  Hypercholesterolemia 64 (40) 11 (46) 53 (39) 0.55b
  Family History 54 (34) 9 (38) 45 (33) 0.82a
  Diabetes Mellitus 24 (15) 3 (13) 21 (16) 1.00a
Cardiac Markers
  Mean Seriald Total CK (U/L) 125.2 (206.4) 144.7 (87.4) 121.6 (221.6) 0.62c
  Mean Seriald MB (ng/ml) 3.01 (19.9) 1.46 (0.89) 3.29 (21.7) 0.68c
  Mean Initial Troponin I (ng/ml) <0.01 <0.01 <0.01 1.0c
  Mean MPO (pM) 83.4 (106.4) 111.9 (173.2) 78.3 (89.6) 0.15c
Mean ACI-TIPI Score 16.8 (15.3) 12.7 (13.5) 17.6 (15.5) 0.17c
TOTAL 159 (100) 24 (15)  135 (85)
Significant p values are in bold; aFisher’s exact test or bchi squared test for categorical variables. cStudent t-test for continuous variables; 
dSerial serum measurements indicate results of the second set drawn after 8 hours. LTFU, lost to follow-up; SD, standard deviation; MI, 
myocardial infarction; CK, creatine kinase; MB, creatine kinase isoenzyme MB; MPO, myeloperoxidase; ACI-TIPI, acute cardiac ischemia 
time insensitive predictive instrument; ng, nanograms; mg, milligrams; U, units; L, liter; ml, milliliter; pM, picomolar.
SD 47.5, CI 37.6-86.1) and without (79.2 pM, SD 91.4, CI 
63.4-96.8) adverse events (p=0.62).
Power Analysis 
Due  to  the  unexpectedly  limited  differences  in  mean 
MPO levels between groups with and without adverse events, 
the present study likely did not achieve the 80% power which 
was calculated a priori. We therefore performed a sensitiv-
ity analysis on the patients lost to follow-up. Assuming the 
worst case scenario in which everyone lost to follow-up had 
an adverse event (i.e. death, MI, or revascularization), the 
MPO levels were not significantly different between groups 
(94.0 ± 23.5, CI 46.3-141.6, t-test p=0.3). 
Distribution of MPO Levels
The  distribution  of  MPO  results  is  visually  demon-
strated in Figure 1. Based on the finding that MPO levels 
were relatively low in patients with adverse events, there 
was not a useful cutpoint to arbitrarily separate patients 
with events from those without events. There were only 
13 patients (5.4% of entire cohort) in the event-free group 
Figure 1.  MPO  distribution  comparing  patients  with  and 
without adverse cardiac events. This jitterplot visually demon-
strates the MPO distribution of all patients in the study. The 
MPO level for each individual patient is represented by a single 
oval. Patients with a 30-day adverse cardiac event are grouped 
to the left, compared with all other patients on the right. There 
was not a useful MPO cutpoint to arbitrarily separate patients 
with events from those without events. MPO, myeloperoxidase 
(picomolar).myeloperoxIdase for chest paIn
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whose MPO levels were lower than all patients in the ad-
verse event group. 
clinical Follow-up
Patients with adverse events are summarized in Table 
3. The 30-day incidence of adverse cardiac events in the 
study population was 5.2%. There were no deaths in the 
study population within 30 days. There were 7 patients with 
at least one adverse cardiac event (among these 7 patients, 
there were 4 myocardial infarctions, 4 percutaneous coro-
nary interventions, and 1 coronary artery bypass graft). 
Univariate Analysis
Results  of  a  univariate  analysis  for  the  association 
between cardiac markers and adverse cardiac events are 
summarized in Table 4. Of the cardiac markers evaluated, 
only serial creatine kinase isoenzyme MB levels (OR 1.7, 
CI 1.08-2.65, p<0.03) significantly predicted 30-day ad-
verse events, while initial creatine kinase isoenzyme MB 
levels showed a trend toward significance (OR 1.5, CI 0.97-
2.2, p<0.08). MPO levels did not predict adverse events 
(OR 0.99, CI 0.98-1.01, p = 0.62). No demographic factors 
(age, sex) or cardiac risk factors (hypertension, diabetes, 
hypercholesterolemia, family history, or current smoking) 
were statistically significant predictors of 30-day adverse 
cardiac events (data from univariate analysis not shown). 
receiver Operating characteristics
The receiver operating characteristics (ROC) of various 
cardiac markers as predictors of 30-day adverse cardiac 
events are demonstrated in Figure 2. Test characteristics 
for MPO as a predictor of adverse events were poor, with 
an ROC curve area of only 0.47 (CI 0.23-0.71). In contrast, 
serial creatine kinase isoenzyme MB was more predictive 
than MPO, with an ROC curve area of 0.75 (CI 0.49-1.0). 
test characteristics of MPO cutpoint
In order to calculate the sensitivity and specificity of 
MPO, we designated an optimal cutpoint. We chose the 
cutpoint (46.7 pM) as the MPO level which minimized 
table 3. Summary of adverse cardiac eventsa
Patient MPO (pM) ED course Inpatient 30-Day Follow-up
1 11.7 NSTEMI LAD Stent Alive
2 19.9 Positive STRESS LAD Stent Alive
3 22.0 STEMI LAD Stent Alive
4 50.1 UAP LAD Stent Alive
5 89.3 SVT NSTEMI Alive
6 111.2 NSTEMI LAD Stent Alive
7 127.6 Positive STRESS CABG Alive
aThe seven patients with 30-day adverse cardiac events are shown in order of ascending 
MPO level. For each patient, any adverse events during the ED course, inpatient course, and 
30-day follow-up are listed. MPO, myeloperoxidase; pM, picomolar; ED, emergency de-
partment; NSTEMI, non-ST elevation myocardial infarction; STEMI, ST-elevation myocar-
dial infarction; UAP, unstable angina pectoris; SVT, supraventricular tachycardia; CABG, 













OR 0 1 2 3
table 4. Univariate analysis of cardiac markers  
as predictors of adverse eventsa
aOdds ratios (OR) are shown for each cardiac marker as a predictor 
of 30-day adverse cardiac events. The OR is represented as a filled 
box, and the 95% confidence interval is represented as a line. MPO, 
myeloperoxidase; CK, creatine kinase; MB, creatine kinase MB 
isoenzymes; OR, odds ratio.myeloperoxIdase for chest paIn
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the difference between the false positive frequency and 
the false negative frequency for 30-day adverse cardiac 
events (17). At this cutpoint, the sensitivity and specificity 
were 57% and 52%, respectively, with a likelihood ratio 
positive (LR+) of 1.18 and a likelihood ratio negative (LR-) 
of 0.83.
DIscUssION
In our low-risk population, MPO was not associated 
with 30-day adverse cardiac events. There was no dif-
ference in mean MPO levels between patients with and 
without  adverse  cardiac  events  in  our  study  (Table  1). 
Due to the relatively low distribution of MPO levels in the 
adverse events group (Figure 1), there was no threshold 
under which a significant subset of patients at low or no 
risk for events could be identified. Using univariate analy-
sis (Table 4), MPO did not predict adverse outcomes (OR 
0.99, CI 0.98-1.01, p=0.62). 
Prior studies
Previous studies suggested that MPO may have utility 
for risk stratification of ED patients with chest pain and 
patients with acute coronary syndromes. Brennan and col-
leagues (10) evaluated 604 consecutive patients presenting 
with chest pain to the emergency department and found 
that for all patients, increasing quartiles of MPO carried 
increased risk (4th quartile OR 4.7) of major adverse car-
diac events (myocardial infarction, re-infarction, revascu-
larization, and death) at 30 days and 6 months. Similarly, 
Baldus and colleagues (11) evaluated 1090 patients with 
acute coronary syndromes enrolled in the CAPTURE (18) 
trial and found that MPO serum levels were predictive of 
subsequent death and myocardial infarction at 6 months 
(adjusted hazards ratio 2.25 between patients with high vs. 
low MPO). Remarkably, for individuals in whom cardiac 
troponin T was initially negative, an elevated MPO level 
at the time of presentation was predictive of subsequent 
major adverse cardiac events in both studies. Neither of 
the above studies reported sensitivity or specificity of an 
MPO cutpoint.  
MPO Risk Stratification
In our study of low risk ED patients with suspected 
myocardial ischemia, the test characteristics for MPO 
were poor (Figure 2), and MPO performed worse than 
two markers of myocardial necrosis (i.e., creatine kinase 
and creatine kinase isoenzyme MB). Furthermore, selec-
tion of an MPO cutpoint using standard techniques for 
clinical decision making (17) yielded disappointing sen-
sitivity and specificity. Despite likely being under-pow-
ered (due to a smaller than expected difference in mean 
MPO levels between groups), a sensitivity analysis as-
suming a “worst case” scenario did not change the results 
of the data analysis. These provocative results suggest 
that MPO has poor utility for individual ED patients with 
chest pain. 
We studied MPO concentrations within 8 hours of ED 
presentation, but it is currently unknown whether the tim-
ing of MPO rise has any clinical significance, as it is not 
a marker ischemia but rather of inflammation. Previous 
studies (10, 11, 18) assessing serum MPO in patients with 
chest pain analyzed concentrations within 18-24 hours of 
presentation or at the time of cardiac catheterization. One 
study in low-risk subjects (19) assessed MPO as part of a 
multi-marker panel in the chest pain unit, but exact tim-
ing of blood measurements were not specified. Therefore, 
our study represents the earliest time at which MPO levels 


























  Area Under the ROC Curve: 
  CK = 0.72 (CI 0.55-0.88) 
Initial MB = 0.66 (CI 0.42-0.90) 
Serial MB = 0.75 (CI 0.49-1.0) 
MPO = 0.47 (CI 0.23-0.71) 
Figure 2. Receiver operating characteristics for cardiac markers 
to predict 30-day adverse events. Shown are ROC curves for the 
initial creatine kinase (CK), initial creatine kinase MB isoen-
zyme (Initial MB), serial creatine kinase MB isoenzyme (Serial 
MB), and base-line values of myeloperoxidase (MPO). The true 
positive fraction (sensitivity) is plotted against the false positive 
fraction (1 - sensitivity) to quantitate the diagnostic accuracy 
of each biologic marker. Areas under the ROC curves were as 
follows: CK = 0.72 (CI 0.55-0.88), Initial MB = 0.66 (CI 0.42-
0.90), Serial MB = 0.75 (CI 0.49-1.0), MPO = 0.47 (CI 0.23-0.71). 
ROC, receiver operating characteristics; CK, creatine kinase; 
MB, creatine kinase isoenzyme MB; MPO, myeloperoxidase; 
CI, 95% confidence intervals.myeloperoxIdase for chest paIn
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One can argue the value of testing a high risk cohort 
(as has been done previously), however testing a low risk 
cohort, as we have done in this study, may have more 
clinical relevance. Mitchell and colleagues (19) used a 
multi-marker  approach  in  low  risk  subjects  and  also 
found that MPO had poor predictive utility for acute cor-
onary syndromes within 45 days. Our goal was to obtain 
objective evidence of plaque instability or ischemia in 
order to justify admission. We found no correlation for 
MPO, which is of interest because it conflicts with work 
from prior studies.  
Our data do not support the use of MPO for risk strati-
fication of a low risk ED patient population with suspected 
myocardial ischemia. By use of the Student’s t-test, ROC 
analysis, univariate analysis, and examination of an opti-
mal cutpoint, we found little support for MPO as a useful 
biomarker to predict short term cardiac outcomes for these 
patients. 
Limitations
The analysis of this data set has several important 
limitations. Selection of non-consecutive patients from 
only one institution, and the low incidence of adverse 
cardiac events in the study cohort may limit conclusions 
about external validity. While our primary analysis was 
likely  underpowered,  our  sensitivity  analysis  did  not 
change  the  conclusions  of  this  study.  Our  composite 
endpoint did not include unstable angina, which may 
increase the association between MPO levels and car-
diac outcomes. Furthermore, use of an independent lab 
to perform the MPO assay limits the generalizability of 
these results. 
Finally,  the  timing  of  any  possible  MPO  elevation 
during acute coronary syndromes is unknown. We drew 
serum within the first 8 hours of presentation to the ED, 
but time of onset of chest pain is not recorded and more 
timely or serial blood draws during the ED course may 
have enhanced detection of an association between MPO 
and adverse events. To avoid these limitations, future stud-
ies might benefit from a larger, consecutive sample taken 
from multiple hospital centers with comparison between 
initial and serial serum MPO levels. 
conclusions
In this small cohort of ED patients with chest pain but 
non-diagnostic ECG and initially negative cardiac tropo-
nin I, serum MPO levels were not associated with 30-day 
adverse cardiac events. Larger, multi-center studies are 
warranted to confirm these findings. 
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